Michael Co­hen on No­var­tis ties: '(T)hey want­ed me to pro­vide ac­cess to gov­ern­ment, in­clud­ing the pres­i­den­t'

Michael Co­hen tes­ti­fy­ing in front of Con­gress (CSPAN).

Michael Co­hen isn’t just call­ing Pres­i­dent — and for­mer client — Don­ald Trump a liar and a con man. He’s al­so claim­ing that phar­ma gi­ant No­var­tis had tried to set him up as a lob­by­ist for the com­pa­ny in an at­tempt to gain di­rect ac­cess to Trump and oth­er in­flu­en­tial gov­ern­ment of­fi­cials.

And that’s a far cry from the way that No­var­tis ex­ecs have char­ac­ter­ized their mo­ti­va­tion be­hind the $1.2 mil­lion con­tract, which they main­tained con­sis­tent­ly was a straight­for­ward but short-lived at­tempt to gain in­sights in­to the Trump ad­min­is­tra­tion’s thoughts on health­care pol­i­cy.

“No­var­tis sent me their con­tract, which stat­ed specif­i­cal­ly that they want­ed me to lob­by,” Co­hen told law­mak­ers in to­day’s high pro­file tes­ti­mo­ny on Capi­tol Hill. “That they want­ed me to pro­vide ac­cess to gov­ern­ment, in­clud­ing the pres­i­dent.”

“That para­graph was crossed out by me, ini­tialed, and writ­ten in my own hand­writ­ing that says I will not lob­by or do gov­ern­ment re­la­tions work,” he con­tin­ued, ac­cord­ing to a tran­script of the re­marks pub­lished by Reuters. 

His re­marks came in re­sponse to ques­tions from Rep. Mark Mead­ows (R-NC), who want­ed to know more about Co­hen’s op­er­a­tions while he was still close to Trump. In the ex­change, Co­hen said he had di­rect­ly in­ter­act­ed with No­var­tis 6 times. And the dis­barred at­tor­ney con­test­ed No­var­tis’ po­si­tion — out­lined by com­pa­ny sources to var­i­ous me­dia out­lets at the time — that he had con­tact­ed the com­pa­ny. No­var­tis, he said, sought him out based “on my knowl­edge of the enig­ma” that Trump is.

Joe Jimenez

No­var­tis’ ex­pla­na­tion — echoed by the re­cent­ly re­tired CEO Joe Jimenez — was that their out­reach to the at­tor­ney was a sim­ple way to gain a bet­ter un­der­stand­ing of the Trump ad­min­is­tra­tion’s ap­proach to health­care poli­cies. Once it be­came ap­par­ent that he could pro­vide lit­tle help, they con­tin­ued, the con­nec­tion end­ed.

Then last year No­var­tis was shak­en to the core by a cor­po­rate cri­sis that erupt­ed around the news that their month­ly pay­ments to Co­hen went in­to the same ac­count that was used to pay off Stormy Daniels, the strip­per who claimed to have had an af­fair with Trump.

A few weeks af­ter the scan­dal broke last sum­mer, a group of De­moc­rats in the Sen­ate re­leased their own quick re­port, con­clud­ing that the com­pa­ny’s con­tention that top ex­ecs had on­ly a brief, in­con­se­quen­tial ex­change with Co­hen and were forced to pay out the con­tract mis­rep­re­sent­ed the nu­mer­ous con­tacts Jimenez had with Co­hen.

“What he was sell­ing was a line of ac­cess to the Trump ad­min­is­tra­tion,” said Sen. Ron Wyden in an in­ter­view with ABC News in Ju­ly. “That would be how I would char­ac­ter­ize it.” Wyden and his col­leagues out­lined nu­mer­ous con­tacts Jimenez had with Co­hen in his last year as CEO, be­fore Vas Narasimhan took the reins.

Vas Narasimhan

No­var­tis re­ject­ed that po­si­tion at the time and quick­ly shut­tered the win­dow on com­ments. It’s stay­ing shut to­day. A spokesper­son for the com­pa­ny told End­points News:

We have pre­vi­ous­ly ad­dressed all ques­tions re­gard­ing our re­la­tion­ship with Es­sen­tial Con­sul­tants and we con­sid­er this mat­ter closed.

CEO Narasimhan has sought to put as much dis­tance as pos­si­ble be­tween him­self and the Co­hen sto­ry, but the com­pa­ny’s ex­pla­na­tions all took part on his watch. In the wake of the news that No­var­tis had paid Co­hen $1.2 mil­lion, the phar­ma gi­ant — which has been in­volved in a string of ethics scan­dals over the years — vowed that it had turned a new leaf. Part of that ef­fort in­volved bring­ing in a promi­nent Ger­man at­tor­ney to lead their ethics, risk and com­pli­ance ef­forts. 

Im­age: Michael Co­hen (Shut­ter­stock)

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

Given the way the FDA has been whisking through new drug approvals months ahead of their PDUFA date, AstraZeneca and their partners Daiichi Sankyo may not have to wait until Q2 of next year to get a green light on trastuzumab deruxtecan (DS-8201).

The pharma giant this morning played their ace in the hole, showing off why they were willing to commit to a $6.9 billion deal — with $1.35 billion in a cash upfront — to partner on the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Large advertisements for the drug Vivitrol decorate the walls of Grand Central Station on June 15, 2017 in New York City. (Photo: Andrew Lichtenstein via Getty)

FDA slaps down Alk­er­mes for mis­lead­ing Viv­it­rol ads — don't for­get vul­ner­a­bil­i­ty to opi­oid over­dose

The ads piqued interest as soon as they started appearing in 2016: at Grand Central Station, on the Red Line in Cambridge, and on a billboard off the New Jersey Turnpike. All showed a young person, generally with his or her arms crossed, and the question, “what is Vivitrol?”

Vivitrol’s maker, Alkermes, was in the midst of a marketing and lobbying campaign to promote the anti-opioid addiction drug — a campaign that would face significant backlash for tarnishing competitors despite little evidence for Vivitrol’s superiority.

FDA in-house re­view spot­lights an is­sue with one of Hori­zon's end­points but notes ef­fi­ca­cy for lead drug

The FDA in-house review highlights a disagreement of investigators’ use of a key endpoint by Horizon Pharma in the late-stage trial for the top drug in its pipeline, but largely agreed that the antibody was effective.

Horizon submitted a BLA for thyroid eye disease (TED) drug teprotumumab in March, less than two years after they bought the drug (and the rest of a division) from Narrow River for $145 million upfront. With breakthrough status, priority review, orphan designation and in-house sales projections of up to $750 million, the one-time Roche reject became the marquee pipeline asset for a company that’s developed some of the world’s most expensive drugs.

Seat­tle Ge­net­ics de­tails pos­i­tive OS and PFS da­ta for tu­ca­tinib in breast can­cer

Seattle Genetics $SGEN is showing off more positive data around tucatinib, its pivotal-stage drug for HER2 positive breast cancer.

A month after hearing about solidly upbeat hazard ratios, we learned today that the estimated progression-free survival rate at one year was 33% in the tucatinib arm compared to 12% for patients taking trastuzumab and capecitabine alone.

Median PFS was 7.8 months (95% CI: 7.5, 9.6) in the tucatinib arm, compared to 5.6 months (95% CI: 4.2, 7.1) in the control arm.

Bat­tered, cash hun­gry In­tec feels the burn of No­var­tis re­jec­tion

It’s a case of some bad timing for Intec.

Just when a key trial testing the company’s Accordion drug delivery tech imploded in Parkinson’s disease, they handed Novartis data from a successful PK study of a custom Accordion pill engineered to deliver a Novartis compound to entice the Swiss drugmaker into signing a licensing agreement.

Novartis said thanks, but no thanks.

For the cash-strapped Israeli drug developer, the failure to clinch the deal marks a big blow. As of the third quarter, the company has $15.7 million in cash and equivalents, which HC Wainwright analysts estimate will keep the lights on into mid-2020.

Paul Hudson, Sanofi

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.

Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class.  The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

Bristol-Myers Squibb reaped an enormous pipeline with its much-criticized $64 billion megadeal to buy Celgene. And it got a few hidden gems in the deal.

One of those gems was brought out for display on Tuesday, with a late-breaker at ASH on CC-486, which is now being prepped for regulatory filings at the FDA and elsewhere.

Celgene top-lined the positive results in a maintenance setting for acute myeloid leukemia a few months ago, but at ASH investigators pulled back the curtains on the all-important data they believe will give them an advantage in the commercial wars to come.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.